Skip to main content
Pharma Mar S.A. logo

Pharma Mar S.A. — Investor Relations & Filings

Ticker · PHM ISIN · ES0169501022 LEI · 959800QWKZ45ZQC2AV58 MC Manufacturing
Open in API
Filings indexed 351 across all filing types
Latest filing 2026-03-23 Regulatory Filings
Country ES Spain
Listing MC PHM

About Pharma Mar S.A.

https://pharmamar.com/en/

Pharma Mar S.A. is a biopharmaceutical company specializing in the discovery, development, and commercialization of oncology treatments derived from marine sources. A pioneer in its field since 1986, the company leverages marine biodiversity to develop innovative therapies for cancer, with a particular focus on rare tumors. Its integrated R&D pipeline spans from the exploration of marine invertebrates to the marketing of approved drugs. The company maintains an extensive collection of over 500,000 marine samples, which serves as the foundation for its drug discovery programs. Key commercialized products include Yondelis® (trabectedin) for advanced soft tissue sarcoma and ovarian cancer, Zepzelca® (lurbinectedin) for small cell lung cancer, and Aplidin® (plitidepsin) for multiple myeloma.

Recent filings

Filing Released Lang Actions
Las autoridades sanitarias de Taiwan aprueban la combinación de Zepzelca® (lurbinectedina) de PharmaMar y atezolizumab (Tecentriq®) en primera línea de mantenimiento para cáncer de pulmón de célula pe
Regulatory Filings Classification · 85% confidence The document is an “Other Relevant Information” notification filed with the Comisión Nacional del Mercado de Valores (CNMV) under article 227 of the Spanish Securities Markets Law. It announces the regulatory approval of PharmaMar’s drug in Taiwan and attaches a press release. This is a corporate regulatory announcement rather than an earnings release, financial report, or other specific category. It therefore falls under the general “Regulatory Filings” fallback category (RNS).
2026-03-23 Spanish
Motivo de la notificación: Persona con Responsabilidad de Dirección
Director's Dealing Classification · 100% confidence The document is a standard form for the notification and public disclosure of transactions by persons discharging managerial responsibilities (PDMR). It explicitly identifies the individual (Soledad Cuenca Miranda), their role (Consejera), the issuer (Pharma Mar, S.A.), and details of the transaction (sale of shares). This aligns perfectly with the definition of 'Director's Dealing' (DIRS).
2026-03-19 Spanish
Motivo de la notificación: Persona con Responsabilidad de Dirección
Director's Dealing Classification · 100% confidence The document is a standard form for the notification and public disclosure of transactions by persons discharging managerial responsibilities (PDMR). It explicitly identifies the individual (Soledad Cuenca Miranda), their role (Consejera), the issuer (Pharma Mar, S.A.), and details of the specific share purchase transaction (date, volume, price). This aligns perfectly with the definition of a Director's Dealing (DIRS) filing.
2026-03-16 Spanish
La Sociedad informa de las operaciones de adquisición de acciones propias en el periodo transcurrido entre el 1 de febrero y el 28 de febrero de 2026.
Transaction in Own Shares Classification · 100% confidence The document is a regulatory filing submitted to the Spanish National Securities Market Commission (CNMV) by Pharma Mar, S.A. It details the company's share buyback program (Adquisición de Acciones Propias) for the period between February 1 and February 28, 2026. The document provides a summary table of daily transactions followed by a detailed annex of individual trades. This falls under the category of 'Transaction in Own Shares' (POS).
2026-03-02 English
La Sociedad remite el Informe Anual sobre remuneraciones de los consejeros del Ejercicio 2025
Remuneration Information Classification · 97% confidence The document is titled 'Informe Anual sobre Remuneraciones de los Consejeros' (Annual Report on Directors' Remuneration) for Pharma Mar, S.A. It details the compensation structure, fixed and variable remuneration, and governance policies regarding executive and board pay for the fiscal year 2025. This type of document is specifically mandated by regulatory requirements (such as the Spanish LSC and CNMV circulars) to be presented to shareholders. In the context of financial reporting, reports detailing executive and director compensation are classified under the 'DEF 14A' category, which covers remuneration information and proxy-related disclosures.
2026-02-27 Spanish
La sociedad remite el Informe Anual de Gobierno Corporativo del ejercicio 2025
Governance Information Classification · 100% confidence The document is an 'Informe Anual de Gobierno Corporativo' (Annual Corporate Governance Report) for Pharma Mar, S.A., filed with the Spanish regulatory body CNMV. It details ownership structure, board composition, and governance practices. While it contains governance information, it is a comprehensive, standardized regulatory report rather than a general governance policy document. In the provided taxonomy, 'CGR' (Governance Information) is the most accurate classification for an Annual Corporate Governance Report.
2026-02-27 Spanish

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.